For more than ten years, TNI’s Drugs & Democracy programme has been studying the UN drug control conventions and the institutional architecture of the UN drug control regime. As we approach the 2016 UNGASS, this primer is a tool to better understand the role of these conventions, the scope and limits of their flexibility, the mandates they established for the CND, the INCB and the WHO, and the various options for treaty reform.
The 2009 Commission on Narcotic Drugs and its High Level Segment (HLS) marked the end of the 2-year process of the 10-year review of the 1998 United Nations General Assembly Special Session (UNGASS) on the World Drug Problem. The event was marked by the call of the President of Bolivia, Evo Morales, to remove the coca leaf from the Single Convention on Narcotic Drugs, which represented the first ever truly open challenge by any nation state to the structure of the international drug control system. The HLS adopted a new Political Declaration and Plan of Action. A dissenting Interpretative Statement by 26 countries on harm reduction, not mentioned in the Political Declaration, marked a clear divide in drug control approaches.
The 51st Commission on Narcotic Drugs (CND) was designated as the point at which the international community would debate the progress made in the 10 years since the Political Declaration of the 1998 UN General Assembly Special Session on Drugs (UNGASS). The 1998 UNGASS called for the eradication or significant reduction of the cultivation, supply and demand of illicit drugs. Few governments acknowledged the real policy dilemmas arising from the failure to achieve these reductions, or came forward with proposals on how the international drug control system could be improved. One of the most debated issues was a resolution on human rights and international drug control introduced by Uruguay.
The 50th Commission on Narcotic Drugs (CND) was the last such event before the watershed year of 2008, when the international community will review progress against the objectives set at the General Assembly Special Session on Drugs (UNGASS), held in New York in 1998. This CND was notable for a significant improvement in civil society involvement in the proceedings – there were a record 81 civil society delegates and NGO representatives included in government delegations. On the other hand, there were repeated moves by some country delegations to marginalise NGO involvement. The global consultation with NGOs to feed in to the UNGASS review process as formally launched.